PAKIANATHAN DEEPIKA sold (to issuer) 64,074 shares of TBPH
PAKIANATHAN DEEPIKA sold (to issuer) 64,074 shares of Theravance Biopharma, Inc. (TBPH) across 2 trades on 2026-09-23.
How this was made
The 30-second read
Why it matters
The director's complete exit may be viewed as a negative signal, but the modest share count limits market reaction.
Market read
Primary insider sale with limited material impact; traders may note but unlikely to drive significant moves.
What to watch
No disclosed price; the transaction may have been part of a pre‑arranged plan or tax considerations.
Background
SEC Form 4 filings provide the first public disclosure of insider transactions.
Ticker impact
Director Pakianathan Deepika sold 64,074 shares, reducing holdings to zero.
Potential modest dip in short term trading.
A director disposing of all shares is uncommon and could be interpreted as a negative signal, though the amount is modest for a listed biotech.
Market effects
Minor impact on biotech sector; insider sales are monitored but this size is not sector‑wide.
Limited to US market where TBPH trades.
Low global relevance.
Counterpoint
The sale could be unrelated to confidence, perhaps for personal liquidity, so price may remain stable.
Key entities
- CompanyTheravance Biopharma, Inc.
Biopharma company listed on Nasdaq under TBPH.
- IndividualPakianathan Deepika
Director of Theravance Biopharma who sold all holdings.
